The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events

被引:12
作者
Scanu A.M. [1 ]
机构
[1] Cardiology Section, Department of Medicine and Biochemistry and Molecular Biology, University of Chicago, Chicago, IL 60637
基金
美国国家卫生研究院;
关键词
D O I
10.1007/s11886-001-0055-4
中图分类号
学科分类号
摘要
Lipoprotein(a) [Lp(a)], is a highly heterogeneous lipoprotein, due to variations in the size of apolipoprotein(a) [apo(a)], and the density of the apoB100-containing particles to which apo(a) is linked. Although high plasma levels of Lp(a) have been associated with an increased risk for atherosclerotic cardiovascular disease, the mechanism underlying this association is still largely undetermined, as is the potential role played by the particle's heterogeneity. Lp(a) pathogenicity may also be influenced by the action of environmental factors and post-translational events relating to oxidative processes, and the action of lipolytic and proteolytic enzymes. Complicating the study of Lp(a) are the competing methods for its quantification due to its complex structure, and the lack of standardized methodologies. The recognition that Lp(a) particles may not all be alike in atherogenic potential should encourage studies to identify genetic and nongenetic factors underlying its heterogeneity, in order to reach a better understanding of its actual impact on atherosclerotic cardiovascular disease. Copyright © 2001 by Current Science Inc..
引用
收藏
页码:385 / 390
页数:5
相关论文
共 33 条
  • [1] Scanu A.M., Lawn R.M., Berg K., Lipoprotein(a) and Atherosclerosis, Ann Int Med, 115, pp. 209-218, (1991)
  • [2] Scanu A.M., Fless G.M., Lipoprotein (a): Heterogeneity and biological relevance, J Clin Invest, 85, pp. 1709-1715, (1990)
  • [3] Scanu A.M., Proteolytic modifications of lipoprotein(a): Potential relevance to its postulated athero-thrombogenic role, J Invest Med, 46, pp. 359-363, (1998)
  • [4] Marcovina S.M., Albers J.J., Scanu A.M., Et al., Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a), Clin Chem, 46, pp. 1956-1967, (2000)
  • [5] Scanu A.M., Lipoprotein(a) - A genetically determined cardiovascular pathogen insearch of a function, J Lab Clin Med, 116, pp. 142-146, (1990)
  • [6] Utermann G., Lipoprotein(a), The Metabolic and Molecular Basis of Inherited Disease, pp. 1887-1912, (1995)
  • [7] Scanu A.M., Edelstein C., Kringle-dependent structural and functional polymorphism of apolipoprotein, Biochim Biophys Acta, 1256, pp. 1-12, (1995)
  • [8] Scanu A.M., Edelstein C., Learning about the structure and biology of human lipoprotein(a) through dissection by enzymes of the elastase family: Facts and speculations, J Lipid Res, 38, pp. 2193-2206, (1997)
  • [9] Scanu A.M., Pfaffinger D., Lee J.C., Hinman J., A single point mutation (Trp72-Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a), Biochim Biophys Acta, 1227, pp. 41-45, (1994)
  • [10] McLean J.W., Tomlinson J.E., Kuang W., Et al., CDNA sequence of human apolipoprotein(a) is homologous to plasminogen, Nature, 330, pp. 132-137, (1987)